Efficacy and toxicity of carboplatin and gemcitabine administered on day 1 and day 8 (day1&8) versus day 1-only for platinum-sensitive recurrent epithelial ovarian cancer.
Erika J LampertPeter G RoseMeng YaoRobert DeBernardoRoberto J VargasChad M MichenerLaura M ChambersPublished in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2023)
There was no difference in response rate, progression-free survival, or overall survival for day 1&8 versus day 1-only, regardless of whether day 8 was dropped. Day 1&8 was associated with greater hematologic toxicity. A modified day 1-only regimen may represent an alternative to day 1&8 and warrants prospective study.